Product Code: TMRGL12197
Genomics Personalized Health Market - Scope of Report
TMR's report on the global genomics personalized health market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global genomics personalized health market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global genomics personalized health market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the genomics personalized health market.
Market Snapshot |
Market Value in 2023 | US$ 9.1 Bn |
Market Value in 2034 | US$ 33 Bn |
CAGR | 12.2% |
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global genomics personalized health market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global genomics personalized health market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global genomics personalized health market.
The report delves into the competitive landscape of the global genomics personalized health market. Key players operating in the global genomics personalized health market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global genomics personalized health market profiled in this report.
Key Questions Answered in Global genomics personalized health Market Report:
- What is the sales/revenue generated by genomics personalized health across all regions during the forecast period?
- What are the opportunities in the global genomics personalized health market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2034?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
Genomics Personalized Health Market - Research Objectives and Research Approach
The comprehensive report on the global genomics personalized health market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global genomics personalized health market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global genomics personalized health market.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Genomics Personalized Health Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution/Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Genomics Personalized Health Market Analysis and Forecast, 2020-2034
5. Key Insights
- 5.1. Pipeline Analysis
- 5.2. Key Product /Brand Analysis
- 5.3. Key Mergers & Acquisitions
- 5.4. COVID-19 Pandemic Impact on Industry
6. Global Genomics Personalized Health Market Analysis and Forecast, By Technology
- 6.1. Introduction & Definition
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast, By Technology, 2020-2034
- 6.3.1. NGS Platform
- 6.3.2. RT-PCR
- 6.3.3. Microarray
- 6.3.4. Genetic Analyzer
- 6.3.5. Others
- 6.4. Market Attractiveness Analysis, By Technology
7. Global Genomics Personalized Health Market Analysis and Forecast, by Test Type
- 7.1. Introduction & Definition
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast, by Test Type, 2020-2034
- 7.3.1. Oncology Testing
- 7.3.2. Infectious Disease Testing
- 7.3.3. Orphan Disease Testing
- 7.3.4. Autoimmune Disease Testing
- 7.3.5. Obstetrics Testing
- 7.3.6. Others
- 7.4. Market Attractiveness Analysis, by Test Type
8. Global Genomics Personalized Health Market Analysis and Forecast, by End-user
- 8.1. Introduction & Definition
- 8.2. Key Findings/Developments
- 8.3. Market Value Forecast, by End-user, 2020-2034
- 8.3.1. Academics & Research Institutes
- 8.3.2. Diagnostic Centers
- 8.3.3. Others
- 8.4. Market Attractiveness Analysis, by End-user
9. Global Genomics Personalized Health Market Analysis and Forecast, by Region
- 9.1. Key Findings
- 9.2. Market Value Forecast, by Region, 2020-2034
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
- 9.3. Market Attractiveness Analysis, by Region
10. North America Genomics Personalized Health Market Analysis and Forecast
- 10.1. Introduction
- 10.2. Key Findings
- 10.3. Market Value Forecast, By Technology, 2020-2034
- 10.3.1. NGS Platform
- 10.3.2. RT-PCR
- 10.3.3. Microarray
- 10.3.4. Genetic Analyzer
- 10.3.5. Others
- 10.4. Market Value Forecast, by Test Type, 2020-2034
- 10.4.1. Oncology Testing
- 10.4.2. Infectious Disease Testing
- 10.4.3. Orphan Disease Testing
- 10.4.4. Autoimmune Disease Testing
- 10.4.5. Obstetrics Testing
- 10.4.6. Others
- 10.5. Market Value Forecast, by End-user, 2020-2034
- 10.5.1. Academics & Research Institutes
- 10.5.2. Diagnostic Centers
- 10.5.3. Others
- 10.6. Market Value Forecast, by Country, 2020-2034
- 10.6.1. U.S.
- 10.6.2. Canada
- 10.7. Market Attractiveness Analysis
- 10.7.1. By Technology
- 10.7.2. By Test Type
- 10.7.3. By End-user
- 10.7.4. By Country
11. Europe Genomics Personalized Health Market Analysis and Forecast
- 11.1. Introduction
- 11.2. Key Findings
- 11.3. Market Value Forecast, By Technology, 2020-2034
- 11.3.1. NGS Platform
- 11.3.2. RT-PCR
- 11.3.3. Microarray
- 11.3.4. Genetic Analyzer
- 11.3.5. Others
- 11.4. Market Value Forecast, by Test Type, 2020-2034
- 11.4.1. Oncology Testing
- 11.4.2. Infectious Disease Testing
- 11.4.3. Orphan Disease Testing
- 11.4.4. Autoimmune Disease Testing
- 11.4.5. Obstetrics Testing
- 11.4.6. Others
- 11.5. Market Value Forecast, by End-user, 2020-2034
- 11.5.1. Academics & Research Institutes
- 11.5.2. Diagnostic Centers
- 11.5.3. Others
- 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
- 11.6.1. Germany
- 11.6.2. U.K.
- 11.6.3. France
- 11.6.4. Italy
- 11.6.5. Spain
- 11.6.6. Rest of Europe
- 11.7. Market Attractiveness Analysis
- 11.7.1. By Technology
- 11.7.2. By Test Type
- 11.7.3. By End-user
- 11.7.4. By Country/Sub-region
12. Asia Pacific Genomics Personalized Health Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Key Findings
- 12.3. Market Value Forecast, By Technology, 2020-2034
- 12.3.1. NGS Platform
- 12.3.2. RT-PCR
- 12.3.3. Microarray
- 12.3.4. Genetic Analyzer
- 12.3.5. Others
- 12.4. Market Value Forecast, by Test Type, 2020-2034
- 12.4.1. Oncology Testing
- 12.4.2. Infectious Disease Testing
- 12.4.3. Orphan Disease Testing
- 12.4.4. Autoimmune Disease Testing
- 12.4.5. Obstetrics Testing
- 12.4.6. Others
- 12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
- 12.5.1. China
- 12.5.2. Japan
- 12.5.3. India
- 12.5.4. Australia & New Zealand
- 12.5.5. Rest of Asia Pacific
- 12.6. Market Attractiveness Analysis
- 12.6.1. By Technology
- 12.6.2. By Test Type
- 12.6.3. By End-user
- 12.6.4. By Country/Sub-region
13. Latin America Genomics Personalized Health Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Key Findings
- 13.3. Market Value Forecast, By Technology, 2020-2034
- 13.3.1. NGS Platform
- 13.3.2. RT-PCR
- 13.3.3. Microarray
- 13.3.4. Genetic Analyzer
- 13.3.5. Others
- 13.4. Market Value Forecast, by Test Type, 2020-2034
- 13.4.1. Oncology Testing
- 13.4.2. Infectious Disease Testing
- 13.4.3. Orphan Disease Testing
- 13.4.4. Autoimmune Disease Testing
- 13.4.5. Obstetrics Testing
- 13.4.6. Others
- 13.5. Market Value Forecast, by End-user, 2020-2034
- 13.5.1. Academics & Research Institutes
- 13.5.2. Diagnostic Centers
- 13.5.3. Others
- 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
- 13.6.1. Brazil
- 13.6.2. Mexico
- 13.6.3. Rest of Latin America
- 13.7. Market Attractiveness Analysis
- 13.7.1. By Technology
- 13.7.2. By Test Type
- 13.7.3. By End-user
- 13.7.4. By Country/Sub-region
14. Middle East & Africa Genomics Personalized Health Market Analysis and Forecast
- 14.1. Introduction
- 14.2. Key Findings
- 14.3. Market Value Forecast, By Technology, 2020-2034
- 14.3.1. NGS Platform
- 14.3.2. RT-PCR
- 14.3.3. Microarray
- 14.3.4. Genetic Analyzer
- 14.3.5. Others
- 14.4. Market Value Forecast, by Test Type, 2020-2034
- 14.4.1. Oncology Testing
- 14.4.2. Infectious Disease Testing
- 14.4.3. Orphan Disease Testing
- 14.4.4. Autoimmune Disease Testing
- 14.4.5. Obstetrics Testing
- 14.4.6. Others
- 14.5. Market Value Forecast, by End-user, 2020-2034
- 14.5.1. Academics & Research Institutes
- 14.5.2. Diagnostic Centers
- 14.5.3. Others
- 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
- 14.6.1. GCC Countries
- 14.6.2. South Africa
- 14.6.3. Rest of Middle East & Africa
- 14.7. Market Attractiveness Analysis
- 14.7.1. By Technology
- 14.7.2. By Test Type
- 14.7.3. By End-user
- 14.7.4. By Country/Sub-region
15. Competition Landscape
- 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
- 15.2. Market Share Analysis, by Company (2023)
- 15.3. Company Profiles
- 15.3.1. QIAGEN
- 15.3.1.1. Company Overview
- 15.3.1.2. Product Portfolio
- 15.3.1.3. SWOT Analysis
- 15.3.1.4. Financial Overview
- 15.3.1.5. Strategic Overview
- 15.3.2. Illumina, Inc.
- 15.3.2.1. Company Overview
- 15.3.2.2. Product Portfolio
- 15.3.2.3. SWOT Analysis
- 15.3.2.4. Financial Overview
- 15.3.2.5. Strategic Overview
- 15.3.3. Thermo Fisher Scientific, Inc.
- 15.3.3.1. Company Overview
- 15.3.3.2. Product Portfolio
- 15.3.3.3. SWOT Analysis
- 15.3.3.4. Financial Overview
- 15.3.3.5. Strategic Overview
- 15.3.4. Bio-Rad Laboratories, Inc.
- 15.3.4.1. Company Overview
- 15.3.4.2. Product Portfolio
- 15.3.4.3. SWOT Analysis
- 15.3.4.4. Financial Overview
- 15.3.4.5. Strategic Overview
- 15.3.5. Hoffmann-La Roche AG
- 15.3.5.1. Company Overview
- 15.3.5.2. Product Portfolio
- 15.3.5.3. SWOT Analysis
- 15.3.5.4. Financial Overview
- 15.3.5.5. Strategic Overview
- 15.3.6. Lonza Group
- 15.3.6.1. Company Overview
- 15.3.6.2. Product Portfolio
- 15.3.6.3. SWOT Analysis
- 15.3.6.4. Financial Overview
- 15.3.6.5. Strategic Overview
- 15.3.7. Invitae Corp
- 15.3.7.1. Company Overview
- 15.3.7.2. Product Portfolio
- 15.3.7.3. SWOT Analysis
- 15.3.7.4. Financial Overview
- 15.3.7.5. Strategic Overview
- 15.3.8. Genetic Technologies Limited
- 15.3.8.1. Company Overview
- 15.3.8.2. Product Portfolio
- 15.3.8.3. SWOT Analysis
- 15.3.8.4. Financial Overview
- 15.3.8.5. Strategic Overview
- 15.3.9. Interleukin Genetics Inc.
- 15.3.9.1. Company Overview
- 15.3.9.2. Product Portfolio
- 15.3.9.3. SWOT Analysis
- 15.3.9.4. Financial Overview
- 15.3.9.5. Strategic Overview
- 15.3.10. Eastern Biotech and Life Sciences
- 15.3.10.1. Company Overview
- 15.3.10.2. Product Portfolio
- 15.3.10.3. SWOT Analysis
- 15.3.10.4. Financial Overview
- 15.3.10.5. Strategic Overview
- 15.3.11. DNA Genotek Inc.
- 15.3.11.1. Company Overview
- 15.3.11.2. Product Portfolio
- 15.3.11.3. SWOT Analysis
- 15.3.11.4. Financial Overview
- 15.3.11.5. Strategic Overview
- 15.3.12. uBiome, Inc.
- 15.3.12.1. Company Overview
- 15.3.12.2. Product Portfolio
- 15.3.12.3. SWOT Analysis
- 15.3.12.4. Financial Overview
- 15.3.12.5. Strategic Overview
- 15.3.13. XCode Life Sciences Private Limited
- 15.3.13.1. Company Overview
- 15.3.13.2. Product Portfolio
- 15.3.13.3. SWOT Analysis
- 15.3.13.4. Financial Overview
- 15.3.13.5. Strategic Overview